Read by QxMD icon Read


Lei Yang, Maowei Yang
Objective This prospective randomized controlled study was performed to determine whether early drug use for osteoporosis impacts bone healing after orthomorphic surgery for hallux valgus (HV) in menopausal patients with osteoporosis. Methods This study included 113 consecutive patients with osteoporosis who underwent a combination of Lapidus arthrodesis and Akin osteotomy for treatment of HV. The patients were randomly divided into a zoledronic acid (ZOL) group (5-mg intravenous injection of ZOL, n = 56) and a placebo group (n = 57); both ZOL and placebo were administered 1 week postoperatively...
January 1, 2018: Journal of International Medical Research
Ramakrishna Dasari, Sunil Misra
This study mainly focuses on the cytogenetic toxicity induction by zoledronic acid (ZA), a nitrogen containing bisphosphonate (N-BPs) in the male germline cells of Swiss albino mice. A single intraperitoneal exposure with three different doses of ZA (2, 4, and 8 mg/kg body weight), toxicity was assessed by analyzing spermatogonial metaphase chromosome aberrations at 24 h, aberrant primary spermatocytes at week 4, and abnormal spermatozoa at week 8 posttreatment. Cyclophosphamide (40 mg/kg) and 0.9% NaCl were used as positive and vehicle controls respectively in the study...
April 12, 2018: Drug and Chemical Toxicology
Mariana Quirino Silveira Soares, Jeroen Van Dessel, Reinhilde Jacobs, Paulo Sérgio da Silva Santos, Tania Mary Cestari, Gustavo Pompermaier Garlet, Marco Antonio Hungaro Duarte, Thaís Sumie Nozu Imada, Ivo Lambrichts, Izabel Regina Fischer Rubira-Bullen
PURPOSE: The aim was to assess the effect of a relevant regimen of zoledronic acid (ZA) treatment for the study of bisphosphonate-related osteonecrosis of the jaw on alveolar bone microstructure and vasculature. A sub-objective was to use 3-dimensional imaging to describe site-specific changes induced by ZA in the alveolar bone. MATERIALS AND METHODS: Five Wistar rats received ZA (0.6 mg/kg) and five (controls) received saline solution in the same volume. The compounds were administered intraperitoneally in 5 doses every 28 days...
March 15, 2018: Journal of Oral and Maxillofacial Surgery
Rahul Naithani, Tulika Seth, Nikhil Tandon, Jagdish Chandra, H Pati, V P Choudhry
No abstract text is available yet for this article.
April 2018: Indian Journal of Hematology & Blood Transfusion
Miku Kuritani, Nobuhiro Sakai, Akiko Karakawa, Motoki Isawa, Masahiro Chatani, Takako Negishi-Koga, Takahiro Funatsu, Masamichi Takami
Denosumab is an anti-bone resorptive drug consisting of complete human monoclonal antibodies that targets receptor activator of nuclear factor κB ligand (RANKL), which is responsible for osteoclast formation. The drug has been adapted for bone diseases, such as osteoporosis and bone metastasis related to cancer, but is not used for alveolar bone destruction related to periodontitis. In the present study, we aimed to clarify whether denosumab prevents bone destruction associated with lipopolysaccharide (LPS)-induced calvaria inflammation and experimental periodontitis in model mice...
2018: Biological & Pharmaceutical Bulletin
Hiroshi Kaise, Fumika Shimizu, Kohei Akazawa, Yoshie Hasegawa, Jun Horiguchi, Daishu Miura, Norio Kohno, Takashi Ishikawa
BACKGROUND: Diagnostic imaging is important for predicting the pathological response to chemotherapy during neoadjuvant chemotherapy (NAC) and for considering the surgical management with appropriate resection after NAC. This study was performed to examine the accuracy of the present radiological imaging for predicting the pathological complete response (pCR). METHODS: From 188 patients in our previous JONIE1 Study, a randomized controlled trial comparing chemotherapy with and without zoledronic acid for patients with human epidermal growth factor receptor 2-negative breast cancer, we evaluated 122 patients whose tumor size was examined by magnetic resonance imaging or ultrasound at three points: before NAC; after administering fluorouracil, epirubicin, and cyclophosphamide; and after NAC...
May 2018: Journal of Surgical Research
Pramod S Sankar, S A Thilak, P Nayak, J P Tripathy, B Satheesan, A V Rajitha
Purpose: Osteonecrosis of the jaw (ONJ) is a rare but complicated side effect of antiresorptive medications. The aim of the study is to evaluate the dental and drug-related factors related to ONJ among patients on these drugs at a tertiary cancer center, India. Methodology: A retrospective record review of patients who received antiresorptive medication at our center from 2011 to 2014 was done. The demographic factors, type, dosage, and duration of the medication and dental history were collected, and the data were entered an analyzed using Epidata software...
January 2018: Contemporary Clinical Dentistry
M Smrecnik, Z Kavcic Trsinar, T Kocjan
Patients with Addison's disease are at greater risk of having reduced bone mineral density and hip fractures and are thus more likely to receive a bisphosphonate than their peers. Potent intravenous bisphosphonates could provoke an acute phase reaction. An 80-year-old female with Addison's disease received her first infusion of zoledronic acid for osteoporosis at our outpatient clinic around noon. Despite doubling her usual afternoon hydrocortisone dose, she became feverish, nauseous, extremely weak, and hypotensive over the night...
March 28, 2018: Osteoporosis International
İbrahim Unal Sert, Ozcan Kilic, Murat Akand, Lutfi Saglik, Mustafa Cihat Avunduk, Esra Erdemli
Introduction: Bisphosphonates are widely used in metastatic cancer such as prostate and breast cancer, and their nephrotoxic effects have been established previously. In this study we aimed to evaluate both the nephrotoxic effects of zoledronic acid (ZA) and the protective effects of vitamin E (Vit-E) on this process under light and electron microscopy. Material and methods: A total of 30 male Sprague-Dawley rats were divided into 3 groups. The first group constituted the control group...
March 2018: Archives of Medical Science: AMS
Andreas Synetos, Konstantinos Toutouzas, Maria Drakopoulou, Iosif Koutagiar, George Benetos, Rafail Kotronias, Nikolaos Anousakis-Vlachochristou, George Latsios, Antonis Karanasos, George Agrogiannis, Marinos Metaxas, Konstantinos Stathogiannis, Aggelos Papanikolaou, Alexandros Georgakopoulos, Nikoleta Pianou, Eleftherios Tsiamis, Efstratios Patsouris, Apostolos Papalois, Dennis Cokkinos, Constantinos Anagnostopoulos, Dimitrios Tousoulis
The aim of this study was to evaluate in an experimental model of aortic valve (AV) stenosis the effectiveness of zoledronate on the inhibition of calcification. Sixteen New Zealand rabbits were placed on vitamin D-enriched diet for 3 weeks. All animals underwent PET/CT at baseline and before euthanasia to assess calcification. Thereafter, the AVs of eight animals were treated with local delivery of 500 μg/l zoledronate. A placebo mixture was administered in the remaining eight animals. Standardized uptake values were corrected for blood pool activity, providing mean tissue to background ratios (TBRmean)...
March 26, 2018: Journal of Cardiovascular Translational Research
Adepitan A Owosho, See Toh Yoong Liang, Adi Z Sax, Kant Wu, SaeHee K Yom, Joseph M Huryn, Cherry L Estilo
OBJECTIVE: The aim of this study was to investigate the relationship between type of antiresorptive medication and medication-related osteonecrosis of the jaw (MRONJ) onset and the role of premedication dental evaluation (PMDE) in the prevention of MRONJ. STUDY DESIGN: Our database of patients with MRONJ was reviewed. The Kruskal-Wallis test was used to analyze the onset dose of the 3 frequent medication types associated with MRONJ. To evaluate the role of PMDE in the prevention of MRONJ, all patients on antiresorptive and/or antiangiogenic medications seen in the Dental Service of Memorial Sloan Kettering Cancer Center during a 10-year period were subclassified into 2 groups...
February 14, 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Noritaka Ohga, Jun Sato, Takuya Asaka, Masahiro Morimoto, Yutaka Yamazaki, Yoshimasa Kitagawa
We report a case of osteonecrosis of the jaw (ONJ) associated with denosumab therapy in a 62-year-old female patient being treated for bone metastases from breast cancer. Upon initial presentation at the Department of Oral Medicine, Hokkaido University Hospital, the patient's mandibular molar teeth were extracted because of severe periodontal disease. Two months later, epithelialization of the sockets was observed and treatment with anti-resorptive drugs was started for bone metastases. One year after tooth extraction, bone exposure in the right lower first molar region was observed, and stage 2 medication-related ONJ (MRONJ) was diagnosed...
2018: Journal of Oral Science
Tomoko Higuchi, Yoshihiko Soga, Misato Muro, Makoto Kajizono, Yoshihisa Kitamura, Toshiaki Sendo, Akira Sasaki
OBJECTIVE: Intravenous zoledronic acid (ZA) is often replaced with subcutaneous denosumab in patients with bone metastatic cancer. Despite their different pharmacologic mechanisms of action, both denosumab and ZA are effective in bone metastasis but cause osteonecrosis of the jaw (ONJ) as a side effect. ZA persists in the body almost indefinitely, whereas denosumab does not persist for long periods. This study evaluated the risks of developing ONJ when replacing ZA with denosumab. STUDY DESIGN: In total, 161 Japanese patients administered ZA for bone metastatic cancer were enrolled in this single-center, retrospective, observational study...
March 6, 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Akeem A Yusuf, Steven R Cummings, Nelson B Watts, Maurille Tepie Feudjo, J Michael Sprafka, Jincheng Zhou, Haifeng Guo, Akhila Balasubramanian, Cyrus Cooper
Studies examining real-world effectiveness of osteoporosis therapies are beset by limitations due to confounding by indication. By evaluating longitudinal changes in fracture incidence, we demonstrated that osteoporosis therapies are effective in reducing fracture risk in real-world practice settings. INTRODUCTION: Osteoporosis therapies have been shown to reduce incidence of vertebral and non-vertebral fractures in placebo-controlled randomized clinical trials. However, information on the real-world effectiveness of these therapies is limited...
March 21, 2018: Archives of Osteoporosis
De-An Qin, Jie-Fu Song, Li-Ping Song, Gui-Sheng Feng
Background Pain management for multiple bone metastases is complex and often requires multidisciplinary treatment. We herein describe patient-centered multidisciplinary pain management for metastatic cancer. CASE PRESENTATION: A 61-year-old woman with multiple bone metastases of uterine cervical cancer developed intractable low back pain. After external beam radiotherapy failed, we performed lumbar spinal intralesional curettage, pedicle screw fixation, and nerve decompression. However, the neuralgia persisted...
January 1, 2018: Journal of International Medical Research
Tongjun Mao, Liang Xu, Yongmei Yu, Zhi Li, Jun Sheng
No abstract text is available yet for this article.
March 15, 2018: Rheumatology
Tanya B Dorff, Neeraj Agarwal
Bone metastases are the main driver of morbidity and mortality in advanced prostate cancer. Targeting the bone microenvironment, a key player in the pathogenesis of bone metastasis, has become one of the mainstays of therapy in men with advanced prostate cancer. This review will evaluate the data supporting the use of bone-targeted therapy, including (1) bisphosphonates such as zoledronic acid, which directly target osteoclasts, (2) denosumab, a receptor activator of nuclear factor-kappa B (RANK) ligand inhibitor, which targets a key component of bone stromal interaction, and (3) radium-223, an alpha-emitting calcium mimetic, which hones to the metabolically active areas of osteoblastic metastasis and induces double-strand breaks in the DNA...
March 16, 2018: Asian Journal of Andrology
Wei Tian, Jun Ma, Ruyi Shi, Chongren Ren, Jiefeng He, Haoliang Zhao
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. γδ T cells have been revealed to be promising candidates for immunotherapy in patients with HCC. However, the use of these cells in clinical practice has been demonstrated to be challenging. In the present study, γδ T cells isolated from the peripheral blood of patients with HCC (n=83) and healthy donors (n=15) were characterized. Flow cytometry was used to analyze the proportion, phenotype, tumor-killing capacity and cytokine secretion of regulatory T cells (Tregs) and γδ T17 cells in peripheral blood samples prior to and following amplification...
April 2018: Oncology Letters
Kenkichi Baba, Hayato Kaida, Chikayuki Hattori, Koichiro Muraki, Tomoko Kugiyama, Hiromasa Fujita, Masatoshi Ishibashi
OBJECTIVE: The purpose of this study was to investigate the palliative and tumoricidal effects of concurrent therapy of strontium-89 chloride (89 SrCl2 ) and zoledronic acid (ZA) for painful bone metastases. SUBJECTS AND METHODS: Fifty-one patients with painful bone metastases prostate cancer (n=17), lung cancer (n=13), breast cancer (n=12), other cancers (n=9) were treated. Bone metastases was confirmed in all patients by technetium-99m hydroxymethylene diphosphonate (99m Tc-HMDP) bone scintigraphy...
March 20, 2018: Hellenic Journal of Nuclear Medicine
Y Yoshioka, E Yamachika, M Nakanishi, T Ninomiya, K Nakatsuji, M Matsubara, N Moritani, Y Kobayashi, T Fujii, S Iida
Bone quality is defined by structural and material characteristics. Most studies on the mandible have focused on the analysis of structural characteristics, with insufficient investigation of material characteristics. This study tested whether zoledronate affects the material characteristics of newly formed mandibular bone. Thirty-six female Wistar rats were assigned to three groups: sham-ovariectomized rats (SHAM, n=12), ovariectomized rats (OVX, n=12), and ovariectomized rats treated with zoledronate (ZOL, n=12)...
March 14, 2018: International Journal of Oral and Maxillofacial Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"